In contrast to the studies investigating non-HER2 SNPs or RNA-related markers, some of these analysed also the potential relationship between HER2 SNPs and known cardiotoxicity clinical risk factors, such as hypertension, in increasing the trastuzumab-related CTRCT. Here, ERBB2 is linked to hypertensive disorder.